Clinical trials: Hepatic Cancer
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
HCC - Hepatocellular Carcinoma, Radiotherapy
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance.
- Trial name
- NCT06870942
- Testing
- Maintenance first-line treatment plus radiation therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
HepatoCellular Carcinoma
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Liver cancer is a common malignant tumor in China, and its incidence rate ranks third and remains high. The treatment of liver cancer has made some progress in recent years, mainly the progress of radical treatment such as…
- Trial name
- NCT04152356
- Testing
- PD-1, Sorafenib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Breast Cancer, eHealth
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects.
- Conditions
- Breast Cancer, eHealth, Symptom Monitoring, Self Management
- Trial name
- eChemoCoach (NCT06424054)
- Testing
- eChemoCoach
- Volunteers
- 746 people
- Sponsor
- Noordwest Ziekenhuisgroep
Primary Liver Cancer
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
- Trial name
- NCT03178929
- Testing
- S-Adenosyl Methionine
- Volunteers
- 207 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Hepatocellular Carcinoma
the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma
evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.
- Trial name
- NCT03777475
- Testing
- transarterial infusion
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatitis C, Chronic
Primary Prevention Hepatocellular Carcinoma by Metformin
Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Chronic, Cirrhosis
- Trial name
- METFOVIR (NCT02319200)
- Testing
- Metformin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Non-intervention observation to evaluate the safety and efficacy of immune checkpoint inhibitors alone or combined with molecular targeted drugs / local interventional therapy in patients with advanced liver cancer, and to…
- Trial name
- NCT05609695
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy…
- Trial name
- NCT04327700
- Testing
- TheraBionic, Regorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave…
- Trial name
- NCT07807475
- Testing
- Hyperpolarized 1-13C -Pyruvate
- Volunteers
- 232 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
- Trial name
- NCT02269995
- Testing
- E7040
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Eisai Co., Ltd.
Liver Cancer, Metastatic Cancer
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.
- Trial name
- NCT00739167
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.
- Trial name
- NCT04053972
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 377 people
- Sponsor
- Sun Yat-sen University
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer
Study of Metatinib Tromethamine Tablet
This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver…
- Conditions
- Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer, Advanced or Metastatic CRC, Advanced or Metastatic Non Squamous NSCLC
- Trial name
- NCT02650375
- Testing
- Metatinib Tromethamine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.
- Trial name
- NCT05886257
- Testing
- Candonilimab, Bevacizumab
- Where
- China
- Sponsor
- Shi Ming